AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening

Anpac Bio has entered into a record, three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management Co., Ltd. in China, which has been a client of the Company for the past two years. This contract contains a minimum of 76,000 paid cancer screening tests.

Read More..

AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60%

AnPac Bio Increases Ownership Percentage of its Subsidiary AnPai Healthcare from 20% to 60% Philadelphia, Pennsylvania, September 3, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the...

AnPac Bio’s USA Laboratory Receives Accreditation from the College of American Pathologists

AnPac Bio’s USA Laboratory Receives Accreditation from the College of American Pathologists Philadelphia, Pennsylvania, August 30, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States...

AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device

AnPac Bio Successfully Completes Major PreClinical Study, Files with National Medical Products Administration (NMPA) for Registration Testing of Its Multi-Cancer CDA Device PHILADELPHIA, Aug. 23, 2021 – via Investor Wire – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company”...

AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO

AnPac Bio Taps Life Sciences and Diagnostics Veteran as US CEO Philadelphia, Pennsylvania, August 17, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...

AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation to Explore Innovative Healthcare and Medical Solutions

AnPac Bio and Roche Pharmaceuticals China Entered into Cooperation to Explore Innovative Healthcare and Medical Solutions Philadelphia, Pennsylvania, August 5, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations...

AnPac Bio Announces Appointment of New Independent Director Independent Director has Strong Track Record at US Fortune 500 Companies

AnPac Bio Announces Appointment of New Independent Director Independent Director has Strong Track Record at US Fortune 500 Companies Philadelphia, Pennsylvania, July 23, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...

AnPac Bio Began Generating Contract Medical Device R&D Revenue Also in Final Stages of Partnership/Cooperation Discussions with Major Corporations

FOR IMMEDIATE RELEASE AnPac Bio Enters into Contract with Cancer Treatment Company JV Partner Philadelphia, Pennsylvania, July 21, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China...

AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Over the Same Period 2020 and Q2 Paid Cancer Tests Increased Approximately 270% Over Q1

FOR IMMEDIATE RELEASE AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Over the Same Period 2020 and Q2 Paid Cancer Tests Increased Approximately 270% Over Q1 Philadelphia, Pennsylvania, July 20, 2021 – AnPac...

AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

FOR IMMEDIATE RELEASE AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds Philadelphia, Pennsylvania, June 18, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...

AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed

AnPac Bio Reports Strong First Quarter in 2021, with 137.2% Increase in Revenue and Record Number of Commercial Tests Completed Philadelphia, Pennsylvania, May 27, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ:...

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture – Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database

AnPac Bio Launches Novel Cancer Treatment Technology and Product Joint Venture - Utilizing Findings from 10 Years of Early-Stage Cancer Detection Work Involving over 222,200 Sample Database  San Jose, CA, May 24, 2021 – AnPac Bio-Medical Science Co., Ltd. (ANPC)...

AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020

AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020 FOR IMMEDIATE RELEASE San Jose, CA., April 30, 2021—AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and...

AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss)

AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss) SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ:...

AnPac Bio to Report Fiscal Year 2020 Financial Results on Friday, April 30, 2021

AnPac Bio to Report Fiscal Year 2020 Financial Results on Friday, April 30, 2021 Earnings Call Scheduled for 8:30 am ET on April 30, 2021 SAN JOSE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac...

AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020

FOR IMMEDIATE RELEASE AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020 San Jose, CA, April 16, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or...

AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved Performance

AnPac Bio Developed and Completed Evaluations of  New Generation Cancer Detection Sensor with Improved Performance San Jose, CA, March 9, 2021 – AnPac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in...

AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement

AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement San Jose, CA, March 5, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused...

China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)

China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility) San Jose, CA, February 8, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a...

AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection | Continues to Innovate and Build Strong IP Portfolio

FOR IMMEDIATE RELEASE AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection |  Continues to Innovate and Build Strong IP Portfolio San Jose, CA, February 1, 2021 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,”...

AnPac Bio Makes Significant Progress in Detecting Pre-cancer Diseases and Recorded Over 20 Types of Pre-cancer Diseases

AnPac Bio Makes Significant Progress in Detecting Pre-cancer Diseases andRecorded Over 20 Types of Pre-cancer Diseases San Jose, CA, December 14, 2020 – AnPac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations...

Anpac Bio Announces Change of Auditor

Anpac Bio Announces Change of Auditor San Jose, CA, December 4, 2020 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer...

AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

FOR IMMEDIATE RELEASE AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020 San Jose, CA, November 25, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a...

Anpac Bio Announces Appointment of New Independent Director

Anpac Bio Announces Appointment of New Independent Director San Jose, CA, November 16, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today...

AnPac Bio US Completes COVID-19 Antibody Test Verification and Approved to Begin Commercial Testing

FOR IMMEDIATE RELEASE AnPac Bio US Completes COVID-19 Antibody Test Verification and Approved to Begin Commercial Testing San Jose, CA, November 10, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company...

AnPac Bio’s Investee Company in China Received COVID-19 Nucleic Acid Test Certification and Began Volume Tests and Collaborations with AnPac Bio

FOR IMMEDIATE RELEASE AnPac Bio’s Investee Company in China Received COVID-19 Nucleic Acid Test Certification and Began Volume Tests and Collaborations with AnPac Bio San Jose, CA, November 2, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company”...

Anpac Bio Completes Over 200,000 Biophysics Based Cancer Detection Tests, With Data Covering Close to 60 Types of Cancer

Anpac Bio Completes Over 200,000 Biophysics Based Cancer Detection Tests, With Data Covering Close to 60 Types of Cancer San Jose, CA, October 26, 2020 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology...

AnPac Bio to Receive Up To USD $8 Million Dollar Grants and Award for R&D, Product Commercialization, and Milestone Achievements

FOR IMMEDIATE RELEASE AnPac Bio to Receive Up To USD $8 Million Dollar Grants and Award for R&D, Product Commercialization, and Milestone Achievements San Jose, CA, October 7, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or...

AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million

FOR IMMEDIATE RELEASE AnPac Bio Announces Equity Investment from Keystone Capital Partners for up to $7 Million San Jose, CA, October 1, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company...

AnPac Bio Receives Major Immunology Testing Contract

FOR IMMEDIATE RELEASE AnPac Bio Receives Major Immunology Testing Contract San Jose, CA, September 15, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...

AnPac Bio Reports First Six Months of 2020 Financial Results

AnPac Bio Reports First Six Months of 2020 Financial Results SAN JOSE, Calif., September 10, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and...

AnPac Bio Announces Positive Results from a Multi-Year Lung Cancer Prognosis and Recurrence Clinical Study

FOR IMMEDIATE RELEASE AnPac Bio Announces Positive Results from a Multi-Year Lung Cancer Prognosis and Recurrence Clinical Study San Jose, CA, September 4, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...

AnPac Bio to Report its First Six Months 2020 Financial Results on Thursday, September 10, 2020

AnPac Bio to Report its First Six Months 2020 Financial Results on Thursday, September 10, 2020 Earnings Call Scheduled for 8:00 am ET on September 10, 2020 San Jose, CA, August 28, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac...

AnPac Bio Philadelphia Lab Gains U.S. CLIA Lab Certification

FOR IMMEDIATE RELEASE AnPac Bio Philadelphia Lab Gains U.S. CLIA Lab Certification San Jose, CA, August 24, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and...

AnPac Bio Opens US Philadelphia Lab Operations

FOR IMMEDIATE RELEASE AnPac Bio Opens US Philadelphia Lab Operations San Jose, CA, August 11, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...

AnPac Bio Validating Approved COVID-19 Antibody Test

FOR IMMEDIATE RELEASE AnPac Bio Validating Approved COVID-19 Antibody Test San Jose, CA, August 7, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...

AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness

FOR IMMEDIATE RELEASE AnPac Bio Announces Preliminary Results From Prospective Trials Indicating Early-Stage Cancer Screening Effectiveness San Jose, CA, August 4, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with...

AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests

AnPac Bio Completes Over 180,000 CDA-Based Cancer Risk Assessment Tests San Jose, CA, July 29, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States...

AnPac Bio Completed 1st Half Year with Increased ASP and Revenue

FOR IMMEDIATE RELEASE AnPac Bio Completed 1st Half Year with Increased ASP and Revenue San Jose, CA, July 13, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in...

AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening

FOR IMMEDIATE RELEASE AnPac Bio Ranked #3 in Liquid Biopsy Clinical Samples Globally by Frost & Sullivan While Retaining #1 Position and Widening its Lead in China in Cancer Screening San Jose, CA, June 26, 2020 – AnPac Bio-Medical Science...

AnPac Bio Launches New Immunology Test Product Line

FOR IMMEDIATE RELEASE AnPac Bio Launches New Immunology Test Product Line San Jose, CA, June 22, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...

AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening

FOR IMMEDIATE RELEASE AnPac Bio Signs a Record Multi-Million Dollar Contract for Cancer Screening San Jose, CA, June 19, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in...

AnPac Bio Announces Appointment of New Chief Financial Officer

San Jose, CA, June 2, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced...

AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent Granted This Year in the United States

AnPac Bio Continues to Build Strong Patent Portfolio, with 3rd Patent  Granted This Year in the United States San Jose, CA, May 26, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology...

AnPac Bio Reports Record Revenue and Number of Cancer Risk Assessment Tests in 2019  

AnPac Bio Reports Record Revenue and Number of Cancer Risk Assessment Tests in 2019   Continued annual revenue growth Number of commercial CDA (cancer differentiation analysis)-based tests increased 26.0% year-on-year Continued to gain customers and increase the acceptance of our...

20-F 2019 Filing

FOR IMMEDIATE RELEASE San Jose, CA., May 18, 2020—AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today...

AnPac Bio Granted New Patent in Novel Medical Device for Disease Detection in the United States

FOR IMMEDIATE RELEASE AnPac Bio Granted New Patent in Novel Medical Device for Disease Detection in the United States San Jose, CA, May 11, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a...

AnPac Bio Receives Accreditation for United States Laboratory from College of American Pathologists

AnPac Bio Receives Accreditation for United States Laboratory from College of American Pathologists SAN JOSE, Calif., March 27, 2020 -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company with operations in China and...

AnPac Bio Granted Important Novel Micro Medical Device Patent in the United States

AnPac Bio Granted Important Novel Micro Medical Device Patent in the United States SAN JOSE, Calif., March 24, 2020 -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (NASDAQ: ANPC), a biotechnology company with operations in China...

AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project

FOR IMMEDIATE RELEASE AnPac Bio Files Coronavirus Detection Patent and Initiates Related Research Project San Jose, CA, February 27, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in...

AnPac Bio Gains Two New Insurance Customers

San Jose, CA, February 6, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, today announced that...

AnPac Bio Announces Pricing of Initial Public Offering

FOR IMMEDIATE RELEASE AnPac Bio Announces Pricing of Initial Public Offering San Jose, CA, January 30, 2020 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio” or the “Company”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United...

ANPAC BIO APPOINTS NOBEL PRIZE WINNER DR. MICHAEL LEVITT AS CHIEF CONSULTANT TO LEAD ANPAC’S PIONEERING EFFORTS IN CANCER SCREENING

ANPAC BIO APPOINTS NOBEL PRIZE WINNER DR. MICHAEL LEVITT AS CHIEF CONSULTANT TO LEAD ANPAC’S PIONEERING EFFORTS IN CANCER SCREENING San Jose, CA – December 11, 2019 – Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio” or the “Company”) announced today...

University of Louisville; Worcester Polytechnic Breast Cancer Study

Investigations on Non-Small Cell Lung Cancer Screening

Anpac Bio Gains U.S. CLIA Lab Certification

AnPac Bio Gains U.S. CLIA Lab Certification  SAN JOSE, California, September 26, 2019 – AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio”), a biotechnology company focusing on early cancer screening and detection, announced that the company's United States subsidiary, has received a certificate of registration under...

Northwestern’s Dr. Lee Shulman Joins Anpac Bio Technical Advisory Board

SACRAMENTO, Calif., Oct. 23, 2018  -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation, Anpac Bio-Medical Science Company (Anpac Bio), announced today that Northwestern University's Dr. Lee P. Shulman, MD, FACMG, FACOG, has joined Anpac Bio's Technical Advisory Board (TAB). It was due to...

Anpac Bio & UC Davis Names 2018 ‘Anpac Bio Innovation & Entrepreneurship Scholars’

Fellowships Fund University of California Entrepreneurship SACRAMENTO, Calif.--(BUSINESS WIRE)--Anpac Bio-Medical Science Company, and the University of California, Davis Mike and Renee Child Institute for Innovation and Entrepreneurship (UCDMRCIIE) selected five accomplished, University of California (UC) scientists to be the 2018 “Anpac Bio-Medical...

Anpac Bio Revenue Surges Nearly 300% After Signing 15th Global Fortune 500 Company Customer

SACRAMENTO, Calif., May 21, 2018  -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, confirmed the company's 2018 revenue vaulted nearly 300% over Anpac Bio's 2017 revenue of the same period, immediately following news reports that Anpac...

Anpac Bio Receives Exceptional Reimbursement Validation: Revenue in Insurance Sector Surges

Anpac Bio Receives Exceptional Reimbursement Validation Revenue in Insurance Sector Surges SACRAMENTO, CA | April 23, 2018 - Anpac Bio-Science Co., Ltd. ("Anpac Bio" hereafter), an international life science company with operations in both Asia and the US, announced today, that...

Anpac Bio Wins 2018 International ‘BIG Innovation Award’

Sacramento, CA – Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced today that Anpac Bio has won the highly prestigious, international, “2018 BIG Innovation Award”. Recognizing the entire corporation for executing significant...

Super Model-Turned-Super Mogul Kathy Ireland Interviews Anpac Bio CEO For ‘Worldwide Business’

Super Model-Turned-SuperMogul Kathy Ireland Interviews Anpac Bio CEO For 'WorldwideBusiness' SACRAMENTO, Calif., April 20, 2018 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, was interviewed this week by "Super Model-turned-Super Mogul"...

Anpac Bio Achieves Milestone of Exceeding Seventy Patents Issued in Twenty Countries/Regions Worldwide

SACRAMENTO, CA | April 16, 2018 –International life sciences and cancer screening technology corporation Anpac Bio-Medical Science Co.,  Ltd. (“Anpac Bio”),  recently achieved a significant milestone of receiving over seventy patents issued in twenty major countries throughout the world. Anpac Bio’s...

Anpac Bio’s Liquid Biopsy Tests Catch 26+ Early-Stage Cancers in Single Blood Test!

SACRAMENTO, Calif., Feb. 7, 2018 /PRNewswire/ -- Anpac Bio-Medical Science Company (Anpac Bio), and its internationally-acclaimed medical research partners, are celebrating  "National Cancer Prevention Day" (#NationalCancerPreventionDay – February 7, 2018) by confirming a new, global milestone: Anpac Bio's proprietary "Cancer Differentiation Analysis" (CDA) liquid biopsy...

Anpac Bio Surpasses 100 Case Milestone Detecting Disease in Patients Deemed ‘Cancer Free’ by Traditional Screening

SACRAMENTO, Calif., Dec. 27, 2017 -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week surpassing a new, international record. Anpac Bio's breakthrough, proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy technology identified the earliest cancer and pre-cancerous disease...

Anpac Bio Wins Global Precision Medicine Industry Award: 2017 ‘Most Promising Cancer Screening Company’

SACRAMENTO, Calif., July 17, 2017 —The Global Precision Medicine Industry Awards leadership named international life sciences corporation Anpac Bio-Medical Science Co., Ltd. ("Anpac Bio"), the 2017, "Most Promising Cancer Screening Company" award winner; in recognition of Anpac Bio's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy cancer screening...

Anpac Bio Surpasses 40,000 Case Study Milestone ‘Liquid Biopsy Pioneer’ Serving Individual, Medical, Insurance & Corporate Customers.

SACRAMENTO, Calif., March 28, 2017 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 40,000 cases worldwide of...

Anpac Bio proud to sponsor the inaugural ‘Anpac Bio World Youth Innovation Forum’, at 2016 World Nobel Prize Laureate Summit, featuring the theme”Serendipity in Science”

Seven Nobel Prize Laureates and over 20 internationally acclaimed researchers and scientists, are presenting at the third annual, "World Nobel Prize Laureate Summit" in Chengdu, China, September 2-3, 2016. The 2016 WNPLS' will feature three programs of scientific exploration: 1)...

Anpac Bio CEO Keynote Speaker at UC Biomedical & Engineering Entrepreneurship Academy

SACRAMENTO, Calif., July 8, 2016  -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, will deliver the Keynote Address to award-winning life and technical science students, faculty, administration, corporate partners, officials, and general public,...

Anpac Bio-Medical Science Pledges $50,000 to UC Davis ChildFamily Institute for innovation and Entrepreneurship

Anpac Fellowships Underwrite University of California Students to Attend Scientific Innovation Academies SACRAMENTO, Calif., Jan. 7, 2016 -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, has pledged $50,000 to the University of California,...

Anpac Bio-Medical Presenting ‘Breakthrough’ Cancer Screening Tech/Research At Breast Cancer Symposium

SACRAMENTO, Calif., Sept. 16, 2015 -- Anpac Bio-Medical Science Company Chief Executive Officer Dr. Chris Yu and Anpac scientists will be presenting "breakthrough," Breast Cancer screening and early detection research results at the upcoming "Breast Cancer Symposium" in San Francisco,...

©2021 Anpac Bio-Medical Science Co., Ltd.